Compositions and methods to detect glua1 in brain and to identify the presence of glua1-mediated ptsd
AssigneeNeurovation Labs, Inc.
InventorJennifer Perusini
Life of this patent
Estimating the term…
Abstract
The present invention provides compositions and methods for detecting GluA1, as a subunit protein and/or as a GluA1-containing, GluA2-lacking AMPAR complex. The invention further provides composition and methods for detecting and/or diagnosing PTSD. The invention further relates to compositions that can be detected using radiological imaging techniques, and processes for performing such imaging techniques using the compositions, to identify elevated GluA1 expression or activity in a subject, which is a biological marker of PTSD.
Claims20
A device for detecting GluA1 protein levels, or GluA1-containing AMPA receptor levels, in a portion of a brain of a subject, comprising:
- a radiation sensing device to detect or quantify radiation levels associated with a radiolabeled composition comprising a ligand of GluA1 protein or a ligand of a GluA1-containing AMPA receptor;
- and
- non-transitory computer-readable memory programmed to perform these steps:
- determining or quantifying, based on a detection or quantification of a first amount of the radiolabeled composition by the radiation sensing device, a GluA1 protein level or GluA1-containing AMPA receptor level in the portion of the brain of the subject;
- providing an indication of the GluA1 protein level or GluA1-containing AMPA receptor level in the portion of the brain of the subject;
- comparing the GluA1 protein level or GluA1-containing AMPA receptor level in the portion of the brain of the subject to a control level of GluA1 protein or GluA1-containing AMPA receptors;
- and
- generating a visual representation of the results of the comparing step.
Dependencies are inferred from the claim text.